Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

AstraZeneca plc (ADR) (AZN) Faces “Tremendous Operational Challenges”

Page 1 of 2

LONDON — Pharmaceutical group AstraZeneca plc (ADR) (NYSE:AZN) was in the headlines at the weekend after the Telegraph anonymously quoted a top-five shareholder speaking out over the uphill struggle facing the FTSE 100 member, while insisting chief executive Pascal Soriot is the right man for the job.

The major shareholder claimed AstraZeneca faces “tremendous operational challenges” to develop a new pipeline of successful products against a backdrop of regulatory hurdles, company restructuring, and austerity-driven pricing.

However, the shareholder apparently remains confident the company is moving in the right direction, by simplifying the business and focusing on organic growth through internal R&D, rather than “disruptive” major takeovers.

AstraZeneca plcAstraZeneca plc (ADR) (NYSE:AZN) could face a potentially awkward annual general meeting this Thursday, after the Local Authority Pension Fund Forum, which owns 2% of the company, advised its members to vote against the “golden hello” pay package awarded to Soriot.

The generous payout, worth up to 11 million pounds this year, includes 1 million pounds in compensation for Soriot’s lost bonus at previous employer Roche.

AstraZeneca responded in a statement:

Our remuneration policy promotes long-term, sustainable growth in shareholder value. We are committed to levels of remuneration that are sufficient to attract, retain and motivate senior employees of the requisite quality, while avoiding paying more than is necessary.

Since joining the company in October, Soriot has made sweeping changes to the company’s management, and in March unveiled a “new strategy to return to growth and achieve scientific leadership.”

In a six-point plain, he emphasized “dramatically simplifying the business,” “rebuilding the R&D engine” and “launching a steady flow of specialty care products.”

Page 1 of 2
Loading Comments...